Faron Pharmaceuticals, located in Helsinki, Finland, is a clinical-stage biopharmaceutical company developing immunotherapies and treatments for severe medical conditions, including cancer and acute organ trauma.
Their lead candidate, bexmarilimab, is a novel macrophage-targeting antibody designed to reprogram immune responses in solid tumors. Another key focus is Traumakine, aimed at treating acute respiratory distress syndrome (ARDS) and preventing vascular leakage. Faron leverages deep scientific research, strong partnerships, and an agile R&D pipeline to bring innovative therapies to patients with unmet medical needs.
Their work is rooted in immunology and precision medicine, with clinical trials conducted across Europe and the U.S. Faron’s mission is to redefine how immune-driven diseases are treated through science-led breakthroughs.
